Niraparib

From WikiMD

Information about Niraparib

  Niraparib is a small molecule inhibitor of poly ADP-ribose polymerase that is used in the therapy of selected patients with refractory and advanced ovarian carcinoma. 

Liver safety of Niraparib

Niraparib therapy is associated with a low rate of transient elevations in serum aminotransferase during therapy, but has not been linked to instances of clinically apparent liver injury

Mechanism of action of Niraparib

Niraparib (nye rap' a rib) is an orally available, small molecule inhibitor of poly adenine diphosphate (ADP)-ribose polymerase (PARP), an enzyme involved in DNA transcription and repair.  Patients with mutations of the BRCA 1 and 2 genes are at increased risk for cancer, particularly ovarian and breast cancer in women.  The BRCA gene encodes DNA repair enzymes, and tumor cells with BRCA mutations have an increased dependence on PARP and increased sensitivity to its inhibition.  Clinical trials of niraparib in women with advanced, refractory ovarian, fallopian tube or primary peritoneal carcinoma have shown response rates of 30% to 40% and prolongation of progression-free survival.  Niraparib is also under evaluation as therapy for advanced breast cancer and other malignant diseases associated mutations in BRCA or other DNA repair enzymes. 

FDA approval information for Niraparib

Niraparib received approval for use in the United States in 2017 for therapy of advanced and refractory advanced, refractory ovarian, fallopian tube or primary peritoneal carcinoma. 

Dosage and administration for Niraparib

Niraparib is available in 100 mg capsules under the brand name Zejula.  The recommended dose is 300 mg by mouth once daily continued until disease progression or unacceptable toxicity occurs. 

Side effects of Niraparib

Common side effects include anemia, fatigue, nausea, diarrhea, constipation, dyspepsia, abdominal pain, anorexia, shortness of breath and thrombocytopenia.  Uncommon, but potentially severe side effects include myelodysplastic syndrome, marked bone marrow suppression, cardiovascular events and embryo-fetal toxicity.

 


The article on Niraparib is a stub. YOU can help Wikimd by expanding it!

Medication resources

Learn more


edit 

About WikiMD

About us: WikiMD is a free medical encyclopedia and wellnesspedia moderated by medical professionals.

Our mission: Provide up to date physician reviewed health, nutrition and wellness information for free in over 100 languages.

Join us: This article is a stub. Help improve Niraparib or others. Do not trust amateurs with your life! Join us in this effort!. Paid editors welcome.

Pubmed.png Uptodate.png Wikipedia Reddit YouTube videos
W8MD weight loss logo

Ad. Tired of being overweight?. W8MD's insurance Weight loss program can HELP*

Quick links: Medicine Portal | Encyclopedia‏‎‏‎ | Gray's Anatomy‏‎ | Topics‏‎ |‏‎ Diseases‏‎ | Drugs | Wellness | Obesity‏‎ | Metabolic syndrome | Weight loss*
Disclaimer: The entire contents of WIKIMD.ORG are for informational purposes only and do not render medical advice or professional services. If you have a medical emergency, you should CALL 911 immediately! Given the nature of the wiki, the information provided may not be accurate, misleading and or incorrect. Use the information on this wiki at your own risk! See full Disclaimer.
Link to this page: <a href="http://www.wikimd.org/wiki/Niraparib">Niraparib</a>

  • Individual results may vary for weight loss from our sponsors.